UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The systemic treatment of recurrent ovarian cancer revisited

Baert, T; Ferrero, A; Sehouli, J; O Donnell, DM; González-Martín, A; Joly, F; Van der Velden, J; ... Ledermann, JA; + view all (2021) The systemic treatment of recurrent ovarian cancer revisited. Annals of Oncology , 32 (6) pp. 710-725. 10.1016/j.annonc.2021.02.015. Green open access

[thumbnail of Ledermann_The Systemic Treatment of Recurrent Ovarian Cancer revisited_Pre-proof.pdf]
Preview
Text
Ledermann_The Systemic Treatment of Recurrent Ovarian Cancer revisited_Pre-proof.pdf - Accepted Version

Download (1MB) | Preview

Abstract

Treatment approaches for relapsed ovarian cancer have evolved over the past decade from a calendar-based decision tree to a patient-oriented biologically driven algorithm. Nowadays, platinum-based chemotherapy should be offered to all patients with a reasonable chance of responding to this therapy. The treatment-free interval for platinum is only one of many factors affecting patients' eligibility for platinum re-treatment. Bevacizumab increases the response to chemotherapy irrespective of the cytotoxic regimen and can be valuable in patients with an urgent need for symptom relief (e.g. pleural effusion, ascites). For patients with recurrent high-grade ovarian cancer, which responds to platinum-based treatment, maintenance therapy with a poly(ADP-ribose) polymerase inhibitor can be offered, regardless of the BRCA mutation status. Here we review contemporary decision-making processes in the systemic treatment of relapsed ovarian cancer.

Type: Article
Title: The systemic treatment of recurrent ovarian cancer revisited
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.annonc.2021.02.015
Publisher version: https://doi.org/10.1016/j.annonc.2021.02.015
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Platinum retreatment, Platinum-based chemotherapy, Recurrent ovarian cancer, poly(ADP-ribose) polymerase (PARP) inhibitor
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre
URI: https://discovery.ucl.ac.uk/id/eprint/10124882
Downloads since deposit
110Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item